Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy

被引：8

作者：

Hennah, Lindsay ^{[1
]}

Seckl, Michael ^{[1
]}

Ghorani, Ehsan ^{[1
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, Dept Med Oncol, London, England

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / 03期

关键词：

Gestational Trophoblastic Disease; NEOADJUVANT IMMUNOTHERAPY; PD-L1; EXPRESSION; SINGLE-AGENT; LUNG-CANCER; CHEMOTHERAPY; THERAPY; PEMBROLIZUMAB; NEOPLASIA; BLOCKADE; DISEASE;

D O I：

10.1136/ijgc-2022-003771

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery that anti-programmed death-1 antibody (anti-PD-1) immunotherapy can cure patients with multidrug-resistant gestational trophoblastic neoplasia provides a new powerful and low toxicity treatment. This heralds an era within which the majority of patients, including those with previously difficult to treat disease, can expect to achieve long-term remission. This development should prompt a rethink of how patients with this rare disease are managed, focusing on maximizing cure rate with minimal exposure to toxic chemotherapy.

引用

页码：414 / 419

页数：6

共 52 条

[1] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics [J].

Akinleye, Akintunde ;

Rasool, Zoaib .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)

[2] EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis [J].

Alifrangis, Constantine ;

Agarwal, Roshan ;

Short, Delia ;

Fisher, Rosemary A. ;

Sebire, Neil J. ;

Harvey, Richard ;

Savage, Philip M. ;

Seckl, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :280-286

[3] Immune checkpoint inhibitor administration during pregnancy: a case series [J].

Andrikopoulou, A. ;

Korakiti, A. M. ;

Apostolidou, K. ;

Dimopoulos, M. A. ;

Zagouri, F. .

ESMO OPEN, 2021, 6 (05)

[4]

[Anonymous], 2017, URG CLIN COMM POL ST

[5] PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes [J].

Bolze, Pierre-Adrien ;

Patrier, Sophie ;

Massardier, Jerome ;

Hajri, Touria ;

Abbas, Fatima ;

Schott, Anne Marie ;

Allias, Fabienne ;

Devouassoux-Shisheboran, Mojgan ;

Freyer, Gilles ;

Golfier, Francois ;

You, Benoit .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (03) :554-561

[6] Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13 [J].

Bolze, Pierre-Adrien ;

Riedl, Cecilia ;

Massardier, Jerome ;

Lotz, Jean-Pierre ;

You, Benoit ;

Schott, Anne-Marie ;

Hajri, Touria ;

Golfier, Francois .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (03) :390.e1-390.e8

[7] Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study [J].

Braga, Antonio ;

Paiva, Gabriela ;

Ghorani, Ehsan ;

Freitas, Fernanda ;

Velarde, Luis Guillermo Coca ;

Kaur, Baljeet ;

Unsworth, Nick ;

Lozano-Kuehne, Jingky ;

Esteves, Ana Paula Vieira dos Santos ;

Filho, Jorge Rezende ;

Amim Jr, Joffre ;

Aguiar, Xianne ;

Sarwar, Naveed ;

Elias, Kevin M. ;

Horowitz, Neil S. ;

Berkowitz, Ross S. ;

Seckl, Michael J. .

LANCET ONCOLOGY, 2021, 22 (08) :1188-1198

[8] Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial [J].

Cheng, Hongyan ;

Zong, Liju ;

Kong, Yujia ;

Wang, Xiaoyu ;

Gu, Yu ;

Cang, Wei ;

Zhao, Jun ;

Wan, Xirun ;

Yang, Junjun ;

Xiang, Yang .

LANCET ONCOLOGY, 2021, 22 (11) :1609-1617

[9]

Cheng HY., 2020, ZHONGHUA FU CHAN KE, V55, P390, DOI DOI 10.3760/CMA.J.CN112141-20191121-00636

[10] Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia [J].

Choi, Min Chul ;

Oh, Jisu ;

Lee, Chan .

EUROPEAN JOURNAL OF CANCER, 2019, 121 :94-97

← 1 2 3 4 5 6 →